25 May 2013
Keywords: china, hep, market, grow, 150m, chinese, hepatitis
Article | 15 September 2008
The Chinese hepatitis C virus drug market, dominated by conventional and pegylated interferons, will more than double by 2012 from $64.0 million
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 September 2008
24 May 2013
© 2013 thepharmaletter.com